VitroScan presents at ESMO24: Chemo response prediction for lung, bladder, and ovarian cancer
15 September 2024
Dr Christi Steendam (Catharina ziekenhuis), dr Debbie Robbrecht (ErasmusMC), and dr. Nelleke Ottevanger present an ex vivo basket trial for chemotherapy response prediction at the ESMO conference in Barcelona. >200 patients were included in the trial.
We're looking back on a great ESMO24 conference, where we shared our poster 'Chemotherapy response prediction for lung, bladder, and ovarian cancer'!
The trial included data from >200 patients (lung, bladder and ovarian cancer) and delivered a prediction model to assess the patients sensitivity to standard of care chemotherapies.
We previously demonstrated that ex vivo tumor testing strongly correlates with clinical outcome for ovarian cancer patients. Strong patient specific response profiles were identified that can provide support for difficult treatment decisions, optimize treatment and facilitate the dialogue between doctor and patients.
.jpg "Collage of VitroScan colleagues presenting their poster at the ESMO 2024 conference")